From 6 weeks through 6 years of age...

Pertussis protection that's there when you need it

DAPTACEL
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed

Please click here for Important Safety Information.
Pertussis remains a threat to infants and children

Incidence rates of pertussis among all age groups in 2012

- Infants under 1 year of age who are not fully vaccinated still have the highest reported rate of pertussis.
- The number of cases in children 6 years of age and younger may represent a reservoir of pertussis that could impact unimmunized or underimmunized infants.
- Infants are at the highest risk for hospitalization and complications from pertussis, which can include pneumonia, seizures, brain swelling, and even death.

Severe pertussis cases are only part of the problem

MILD PERTUSSIS

- Toddlers and children 6 years of age and younger who have mild disease can transmit *Bordetella pertussis* bacteria to others.
- Persons with mild cases can still be contagious and, because they often lack the classic paroxysmal cough, go unrecognized and undiagnosed.
- Undiagnosed cases of mild pertussis can be the source of infant infection.

SEVERE PERTUSSIS

- Protection against severe disease is expected from a pertussis vaccine—but mild disease can't be ignored.
- Steps must be taken to help protect against any case, including both mild and severe disease.

Please click here for Important Safety Information.
Highly protective against all severities of pertussis\textsuperscript{6,a}

DAPTACEL vaccine efficacy against pertussis\textsuperscript{6,b}

<table>
<thead>
<tr>
<th>% Protective Efficacy</th>
<th>All Severities of Pertussis (\geq 1 day of cough with laboratory-confirmed pertussis)</th>
<th>Severe/WHO\textsuperscript{c}-defined Pertussis (\geq 21 days of paroxysmal cough)</th>
</tr>
</thead>
<tbody>
<tr>
<td>78%</td>
<td><strong>Protective Efficacy in the prevention of all severities of pertussis, including mild disease</strong>\textsuperscript{6}</td>
<td><strong>Protective Efficacy in the prevention of severe disease</strong>\textsuperscript{6}</td>
</tr>
</tbody>
</table>

\(\text{a}\) Including cases with as little as 1 day of cough following the third dose in a randomized, double-blind, culture-confirmed, diphtheria and tetanus vaccine-controlled, National Institutes of Health-sponsored trial.\textsuperscript{6}

\(\text{b}\) 2587 infants given DAPTACEL vaccine.\textsuperscript{6}

\(\text{c}\) WHO = World Health Organization.

\(\text{d}\) DTaP = Diphtheria, tetanus, and acellular pertussis.

• DAPTACEL vaccine is indicated for the DTaP\textsuperscript{d} booster dose at 4-6 years of age, which may be the last opportunity to vaccinate prior to elementary school\textsuperscript{7}

Sanofi Pasteur offers a portfolio of pediatric products

- Pentacel®: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine
- Fluzone®: INFLUENZA VIRUS VACCINE
- Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
- Menactra®: Meningococcal (Groups A,C,Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- DAPTACEL®: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- ActHIB®: Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)

Visit VaccineShoppe.com® for savings and ordering convenience

• One-stop online ordering
• Competitive pricing (not based on volume)
• Upfront, online, and prompt-pay discounts

Please click here for Important Safety Information.
IMPORTANT SAFETY INFORMATION

INDICATION

DAPTACEL vaccine is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children 6 weeks through 6 years of age (prior to seventh birthday).

SAFETY INFORMATION

The most common local and systemic adverse reactions to DAPTACEL vaccine include injection site redness, swelling, and tenderness; fever, irritability, drowsiness, and crying more than usual. Other adverse reactions may occur. DAPTACEL vaccine is contraindicated in persons with any immediate anaphylactic reaction or hypersensitivity to any component of the vaccine.

The decision to give DAPTACEL vaccine should be based on the potential benefits and risks; if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid; or if adverse events have occurred in temporal relation to receipt of pertussis-containing vaccine. Apnea following intramuscular vaccination has been observed in some infants born prematurely. Encephalopathy within 7 days of administration of a previous dose of a pertussis-containing vaccine or a progressive neurologic disorder is a contraindication. Vaccination with DAPTACEL vaccine may not protect all individuals.

Before administering DAPTACEL vaccine, please click here for full Prescribing Information.